SummerHaven Investment Management LLC Buys 464 Shares of Semler Scientific Inc. $SMLR

SummerHaven Investment Management LLC increased its stake in Semler Scientific Inc. (NASDAQ:SMLR) by 2.0% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 23,570 shares of the company’s stock after purchasing an additional 464 shares during the quarter. SummerHaven Investment Management LLC owned approximately 0.17% of Semler Scientific worth $913,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. Interchange Capital Partners LLC purchased a new position in shares of Semler Scientific during the 1st quarter valued at $46,502,000. Charles Schwab Investment Management Inc. grew its position in shares of Semler Scientific by 226.1% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 158,576 shares of the company’s stock valued at $5,740,000 after purchasing an additional 109,951 shares in the last quarter. Pacer Advisors Inc. purchased a new position in shares of Semler Scientific during the 1st quarter valued at $1,874,000. Nomura Holdings Inc. purchased a new position in shares of Semler Scientific during the 1st quarter valued at $1,295,000. Finally, Capital Fund Management S.A. purchased a new position in shares of Semler Scientific during the 1st quarter valued at $1,103,000. Institutional investors own 49.37% of the company’s stock.

Semler Scientific Price Performance

SMLR stock opened at $28.31 on Monday. Semler Scientific Inc. has a 1 year low of $22.22 and a 1 year high of $81.56. The company has a market cap of $419.27 million, a P/E ratio of 11.65 and a beta of 1.39. The firm has a 50-day moving average of $32.54 and a 200 day moving average of $35.35. The company has a debt-to-equity ratio of 0.25, a current ratio of 0.60 and a quick ratio of 0.58.

Semler Scientific (NASDAQ:SMLR) last released its quarterly earnings results on Monday, August 4th. The company reported $5.04 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.27) by $5.31. Semler Scientific had a net margin of 86.20% and a return on equity of 43.84%. The company had revenue of $8.22 million during the quarter, compared to the consensus estimate of $8.10 million.

Wall Street Analysts Forecast Growth

SMLR has been the subject of several research reports. Cantor Fitzgerald cut their target price on shares of Semler Scientific from $61.00 to $60.00 and set an “overweight” rating for the company in a research report on Wednesday, August 6th. Maxim Group cut their target price on shares of Semler Scientific from $95.00 to $80.00 and set a “buy” rating for the company in a research report on Friday, September 19th. Finally, Benchmark cut their target price on shares of Semler Scientific from $101.00 to $86.00 and set a “buy” rating for the company in a research report on Tuesday, September 23rd. Four research analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, the stock currently has an average rating of “Buy” and an average target price of $74.25.

Semler Scientific Company Profile

Semler Scientific, Inc provides technology solutions to enhance the clinical effectiveness and efficiency of healthcare providers in the United States. The company’s products include QuantaFlo, a four-minute in-office blood flow test that enables healthcare providers to use blood flow measurements as part of their examinations of a patient’s vascular condition.